AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8567331
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hyperfractional radiotherapy with bronchial arterial infusion of anticancer drugs (Group 1, 30 cases)
Trial: 7043008
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg four times daily for seven days)
Trial: 7991070
Drug: Thyrotropin-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin-releasing hormone (TRH, 500 micrograms)
Trial: 7991070
Drug: GH-releasing hormone
RxNorm normalized name: thyrotropin-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH-releasing hormone (GHRH, 100 micrograms)
Trial: 31641887
Drug: Voglibose (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose (0.6 mg/day)
Trial: 28779371
Drug: No drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drugs (control)
Trial: 17400624
Drug: Trust in
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trust in pharmaceutical industry and doctors
Trial: 12034600
Drug: 80 mL
RxNorm normalized name: urinary bag 480 mL MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mL of the same contrast agent injected at a 4 mL/sec flow rate
Trial: 30776899
Drug: Prebiotic inulin‐type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic inulin‐type fructans (6 g/day)
Trial: 30776899
Drug: Prebiotic inulin‐type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic inulin‐type fructans during antibiotic treatment
Trial: 21948500
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT) during HBOT
Trial: 19807887
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml x kg(‐1) of 1% lidocaine with epinephrine 0.5 microg x kg(‐1)
Trial: 16780671
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg/d
Trial: 2888651
Drug: Adenosine (1/3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (1/3, 2/3, and full maximum tolerable dose)
Trial: 2888651
Drug: Metoprolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (10 mg to males, 8 mg to females)
Trial: 31539289
Drug: Thigh administration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thigh administration
Trial: 26689403
Drug: Various metabolic
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various metabolic treatment strategies
Trial: 19742382
Drug: No choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No choice group (participants were assigned to their preferred treatment but believed they couldn't choose)
Trial: 19742382
Drug: Wait-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-list control group (participants received no treatment until the end of the study)
Trial: 10439770
Drug: Ramosetron 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.3 mg
Trial: 12904147
Drug: Management strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management strategies for anticoagulant-related bleeding
Trial: 15876307
Drug: Allergen inhalation
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen inhalation
Trial: 27251666
Drug: Restrictive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive blood transfusion strategy (Hb levels ≥9.7 g/dL)
Trial: 21654270
Drug: 40 mg/d
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/d febuxostat
Trial: 21654270
Drug: 60 mg/d
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/d febuxostat
Trial: 11280362
Drug: Self-tapping implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-tapping implants
Trial: 11280362
Drug: ICE implants
RxNorm normalized name: Camphor Ice Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICE implants
Trial: 11280362
Drug: Both self-tapping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both self-tapping and ICE implants
Trial: 16754218
Drug: No cryo-preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cryo-preparation (standard local anaesthetic injection)
Trial: 31494254
Drug: Probiotic Vivomixx®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Vivomixx® (2 sachets twice daily for 2 months)
Trial: 25415784
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections
Trial: 25415784
Drug: Lumbar interlaminar
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumbar interlaminar epidural injections with local anesthetic only
Trial: 25415784
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections with local anesthetic and steroid
Trial: 22622911
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections with local anesthetic only
Trial: 25415784
Drug: Lumbar interlaminar
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumbar interlaminar epidural injections with local anesthetic and steroid
Trial: 22721899
Drug: Vi capsular
RxNorm normalized name: typhoid vaccine VI capsular polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi capsular polysaccharide (ViCPS) vaccine
Trial: 18325758
Drug: Testosterone patch
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone patch 30 cm2 (0.5mg/cm2)
Trial: 18325758
Drug: Testosterone patch
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone patch 45 cm2 (0.5mg/cm2)
Trial: 18325758
Drug: Testosterone patch
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone patch 60 cm2 (0.5mg/cm2)
Trial: 7684118
Drug: Isoprinosine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprinosine (3 g/day)
Trial: 25612299
Drug: Ponesimod 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponesimod 2.5 mg b.i.d.
Trial: 25612299
Drug: Ponesimod 5
RxNorm normalized name: ponesimod 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponesimod 5 mg b.i.d.
Trial: 25612299
Drug: Ponesimod 10
RxNorm normalized name: ponesimod 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponesimod 10 mg q.d.
Trial: 25612299
Drug: Ponesimod 20
RxNorm normalized name: ponesimod 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponesimod 20 mg q.d.
Trial: 25612299
Drug: Ponesimod 20
RxNorm normalized name: ponesimod 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponesimod 20 mg single dose after washout period
Trial: 25612299
Drug: Ponesimod 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponesimod 2.5 mg b.i.d. and 5 mg b.i.d. morning doses
Trial: 16768642
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate (MPH) 18-72 mg/day
Trial: 9266276
Drug: ABT-299 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-299 0.8 mg
Trial: 9266276
Drug: ABT-299 2
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-299 2 mg
Trial: 3822616
Drug: griseofulvin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: griseofulvin (15 mg/kg/day)
Trial: 3822616
Drug: ketoconazole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoconazole (5 mg/kg/day)
Trial: 17419956
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (sham treatment)
Trial: 22503494
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 1000 mg of paracetamol
Trial: 16094267
Drug: Dilute betadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilute betadine solution irrigation (3.5% betadine) before wound closure
Trial: 7518815
Drug: Combined external
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined external irradiation and chemotherapy (bleomycin or peplomycin)
Trial: 2923425
Drug: Regulated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regulated group (n = 41) received hourly aliquots of oral fluid as determined by twice daily ward rounds.
Trial: 29698720
Drug: Lidocaine dripped
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine dripped onto the skin prior to injection (1-2 ml)
Trial: 29698720
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (1% subcutaneous lidocaine injection without prior skin application)
Trial: 29698720
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group for peripherally inserted central catheters (1% subcutaneous lidocaine injection without prior skin application)
Trial: 25463092
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba treatment for 2 months
Trial: 11980742
Drug: Conscious sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conscious sedation (2 mg midazolam and 25 microg fentanyl) i.v. 5 min before cervical dilatation
Trial: 8828420
Drug: Laparoscopic local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic local methotrexate injection
Trial: 1592955
Drug: CMT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMT plus AST (Adjunctive Ally Support Training)
Trial: 30678333
Drug: Caffeine supplementation
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine supplementation (6 mg·kg−1)
Trial: 25424810
Drug: rMenB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rMenB with reduced OMV doses (0, ¼ or ½ the OMV dose)
Trial: 25424810
Drug: Half-dose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose of 4CMenB
Trial: 25424810
Drug: Prelicensure formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prelicensure formulation of 4CMenB
Trial: 25424810
Drug: 4CMenB (4-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB (4-dose primary/booster series)
Trial: 17050578
Drug: Tobramycin 0.3%,
RxNorm normalized name: Tobramycin 0.3%, Dexamethasone 0.1% Ophthalmic drops, suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 0.3%, 1 drop every two hours for 2 days, then four times daily for 5 days
Trial: 11382537
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS) consisting of 30 trains of 2‐s duration stimuli (20 Hz, 90% of motor threshold), after 10 daily sessions.
Trial: 9264868
Drug: 17 beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta‐estradiol (50 micrograms transdermally or 2 mg orally)
Trial: 8353409
Drug: Ethinylestradiol 40
RxNorm normalized name: Ethinylestradiol 40 microgram and levonorgestrel 75 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol 40 micrograms twice daily
Trial: 8353409
Drug: Ethinylestradiol 20
RxNorm normalized name: Ethinylestradiol 20 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol 20 micrograms four times daily
Trial: 28283779
Drug: ME-344 10
RxNorm normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ME-344 10 mg/kg intravenously weekly plus topotecan 4 mg/m2 on days 1, 8, and 15 of a 28 day cycle
Trial: 23001292
Drug: alfentanil 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 20 μg/kg
Trial: 12888778
Drug: ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine 0.5 mg/kg
Trial: 19893466
Drug: Sodium hypochlorite
RxNorm normalized name: Sodium hypochlorite
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium hypochlorite with the adjunct of a proteolytic enzyme
Trial: 16402229
Drug: Oily calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oily calcium hydroxide suspension (Osteoinductal) applied subgingivally after nonsurgical periodontal therapy
Trial: 14766981
Drug: Posttrial infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Posttrial infusion of 0.75 mg of the cholinesterase inhibitor physostigmine
Trial: 9234039
Drug: Saline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (1 ml i.v.) administered on 1 day
Trial: 28974567
Drug: On-treatment mean
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment mean systolic blood pressure (SBP)
Trial: 26288199
Drug: SFC (25/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC (25/125 mcg) through BAI
Trial: 26288199
Drug: SFC (25/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC (25/125 mcg) through pMDI
Trial: 21288053
Drug: Esomeprazole (more
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (more effective acid inhibitor)
Trial: 21288053
Drug: Standard PPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard PPI treatment (control)
Trial: 11584993
Drug: Azoles and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azoles and other formulations of amphotericin B
Trial: 9227167
Drug: Oral hydroxychloroquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydroxychloroquine (HCQ)
Trial: 3117402
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of adriamycin (20 mg/40 ml or 30 mg/30 ml)
Trial: 3117402
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of mitomycin C (20 mg/40 ml)
Trial: 3117402
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation of thio-TEPA (30 mg/30 ml)
Trial: 3117402
Drug: Noninstillation treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninstillation treatments with etretinate or tegafur
Trial: 25683060
Drug: Neurokinin B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurokinin B (NKB) administration
Trial: 25683060
Drug: Vehicle (placebo)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (placebo) infusion
Trial: 21684508
Drug: Aspirin 50
RxNorm normalized name: aspirin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 50 mg
Trial: 10718778
Drug: Sibrafiban/Ticlopidine/Aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibrafiban/Ticlopidine/Aspirin
Trial: 30293295
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg carboprost methylate suppository
Trial: 23782001
Drug: vitamins and
RxNorm normalized name: multivitamins and iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamins and minerals (vit&min) treatment (group A; N.274)
Trial: 23782001
Drug: calcium/vitamin D3
RxNorm normalized name: calcium/vitamin D3 ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium/vitamin D3 treatment (group B; N.278)
Trial: 21832831
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (SCIT) with birch extract
Trial: 21832831
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with birch extract
Trial: 17576867
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg BID
Trial: 17576867
Drug: Rivaroxaban 30
RxNorm normalized name: rivaroxaban 30-Day Starter Pack (42-15 MG Oral Tablets & 9-20 MG Oral Tablets)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 30 mg BID
Trial: 18621928
Drug: Rivaroxaban 40
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 40 mg once daily
Trial: 17576867
Drug: Enoxaparin/vitamin K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin/vitamin K antagonist
Trial: 14991935
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g twice daily for 1 week (Group I)
Trial: 14991935
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g twice daily for 2 weeks (Group II)
Trial: 11458720
Drug: Midazolam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1 mg/kg b.w.)
Trial: 11458720
Drug: Midazolam (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (for treatment of severe agitation)
Trial: 9715356
Drug: Cocaine-alcohol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine-alcohol (4 doses of intranasal cocaine 1 mg/kg every 30 min with oral alcohol 1 g/kg)
Trial: 9715356
Drug: Cocaine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (4 doses of intranasal cocaine 1 mg/kg every 30 min)
Trial: 9715356
Drug: Alcohol (4
RxNorm normalized name: POLYVINYL ALCOHOL (40000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (4 doses of oral alcohol 1 g/kg)
Trial: 9715356
Drug: Cocaine placebo
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine placebo (4 doses of placebo cocaine)
Trial: 9715356
Drug: Alcohol placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol placebo (4 doses of placebo alcohol)
Trial: 22639289
Drug: Intensive glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemic control (IGC) for almost 24 h after PCI (n = 82; glucose, 80‐140 mg/dl)
Trial: 22639289
Drug: Conventional glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glycemic control (CGC; n = 83; glucose, 180‐200 mg/dl)
Trial: 20053938
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid and 30 mg iron (Fe30Fol)
Trial: 8171949
Drug: Hypnotics (etomidate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnotics (etomidate, midazolam, propofol)
Trial: 24172159
Drug: Hypnotics
RxNorm normalized name: HYPNOTICS AND SEDATIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnotics
Trial: 8171949
Drug: Various hypnotics
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various hypnotics
Trial: 27401514
Drug: Telephone-based symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based symptom management (TSM) consisting of cognitive-behavioral and emotion-focused therapy
Trial: 22741257
Drug: Surrounding needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surrounding needling of electroacupuncture and hot compress of Chinese medicine
Trial: 19027437
Drug: Control (sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (sham therapy or wait-list)
Trial: 16050413
Drug: Combined treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatments with selective drugs
Trial: 10591711
Drug: Hypericum extract
RxNorm normalized name: Hypericum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum extract (1050 mg, 350 mg three times daily)
Trial: 10591711
Drug: Imipramine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (100 mg, 50 mg, 25 mg, and 25 mg daily)
Trial: 21364503
Drug: Lidocaine 40
RxNorm normalized name: lidocaine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 40 mg
Trial: 1283888
Drug: Mexiletine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (300 mg/day)
Trial: 15028073
Drug: Disopyramide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide (300 mg/day)